CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(ICI) on on 3-year Event Free Survival (EFS), in women with residual hormone receptor negative, HER2-negative ("triple negative") resectable breast...
Phase 2
Los Angeles, California, United States and 3 other locations
A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of C...
Phase 1
Beverly Hills, California, United States and 3 other locations
The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a ...
Phase 1, Phase 2
Los Angeles, California, United States and 9 other locations
Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast...
Phase 2
Los Angeles, California, United States and 18 other locations
Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies avail...
Phase 3
Los Angeles, California, United States and 78 other locations
in combination with either of two chemotherapy regimens (weekly paclitaxel or capecitabine) in unresectable/metastatic triple negative breast...
Phase 1, Phase 2
Los Angeles, California, United States of America and 1 other location
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd...
Phase 2
Los Angeles, California, United States and 32 other locations
of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants with HR+/HER2- advanced/metastatic breast...
Phase 1, Phase 2
Los Angeles, California, United States and 6 other locations
This will be a Phase 2 clinical trial to assess somatostatin receptor (SSTR) expression in Stage IV estrogen receptor positive (ER+) breast ...
Phase 2
Irvine, California, United States
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer....
Phase 3
Sylmar, California, United States and 319 other locations
Clinical trials
Research sites
Resources
Legal